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Abstract 
 
Background: Modafinil, a non-amphetamine central nervous system stimulant, is a wakefulness-promoting agent indicated for use in 
shift work sleep disorder, narcolepsy, and obstructive sleep apnea. The trend in modafinil overexposure over a ten-year period and 
the population likely to experience a resulting clinical effect is evaluated. 
Methods: Using data from the American Association of Poison Control Center (AAPCC) National Poison Data System (NPDS), a 
retrospective review of all reported modafinil overexposures over a ten-year period (2001-2010) was conducted. In order to 
determine whether age, reason and acuity had a role in predicting medical outcome, odds ratios (OR) were calculated using binomial 
logistic regression analysis.   
Results: There were 1,100 modafinil overexposures reported with known outcomes, of which 600 cases (54%) were women and 367 
(33%) were ≤ 5 years old. Seventy-seven percent of the exposures were acute ingestions and the majority was unintentional. The 
number of reported modafinil exposures increased with time until 2007. Adults were more likely to have an adverse effect than 
children ≤ 5 years of age. Patients with an intentional overexposure were more likely to have an effect than those with an 
unintentional overexposure (OR = 5.2; 95% CI 3.9-7.1; P < 0.001).  
Conclusion: The frequency of reported modafinil exposures increased with time until 2007. The majority of exposures resulted in no 
adverse clinical effect. Older patients and those with intentional exposure were more likely to experience a clinical effect.  
 
Keywords: Central Nervous System Stimulants; Drug Overdose; Modafinil; Poison Control Centers; United States 
 
 
Retrospective Review of Trend in Modafinil Overexposures 
Reported to American Poison Information Centers  
 
50 
(GABA) release and increase glutamate release in the 
hippocampus and thalamus (11). Additionally, it is known to 
increase extracellular concentrations of dopamine, 
norepinephrine, serotonin, glutamate, and histamine (11). 
However, unlike the amphetamines, modafinil does not have an 
effect on spontaneous dopamine release. The standard therapeutic 
dose of modafinil in adult patients is 200-400 mg daily. 
A search of the medical literature revealed limited 
information regarding supratherapeutic modafinil ingestions. 
During clinical trials, ingestions of doses up to 4,500 mg 
were reported without any life-threatening toxicity (1). 
Clinical effects of these supratherapeutic ingestions were 
evaluated in two studies and 2 case reports (2,3,12,13). 
Available information suggests that the most common 
clinical effects include tachycardia, insomnia, agitation and 
headache (2,3). The majority of ingestions, however, 
resulted in either minor severity or an absence of effects 
(2,3). Both Spiller et al. and Carstairs et al. found that the 
majority of ingestions reported to a limited number of 
American poison control centers involved patients less than 
6 years of age (2,3). No deaths associated with modafinil 
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Modafinil (2[(diphenylmethyl) sulfinyl] acetamide) is a 
non-amphetamine central nervous system stimulant that is 
used as a wakefulness-promoting agent (1-3). Approved by 
the Federal Drug Administration (FDA) in 1998 under the 
brand name Provigil®, it is indicated for the treatment of 
drowsiness associated with narcolepsy, obstructive sleep 
apnea and shift work sleep disorder (2,3). Due to its 
presumed lower potential for abuse and lack of peripheral 
sympathomimetic effects that are associated with the 
amphetamine stimulants, it has also been studied and used 
off-label to treat sedation in other conditions such as 
Parkinsonism, fatigue in human immunodeficiency virus 
(HIV) infection, multiple sclerosis, cancer, and attention 
deficit hyperactivity disorder (ADHD) (4-8). Other off-label 
uses include the treatment of cocaine dependence and 
withdrawal, alcoholic organic brain disorder, and as adjunct 
therapy in depression (2,3,9,10).   
The mechanism of action of modafinil is complex and poorly 
understood. It is known to cause a decrease in - aminobutyric 
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overdose alone have been reported (1).  
Due to the off-label use for cognitive enhancement in 
psychiatric disorders such as schizophrenia and ADHD, 
modafinil and other stimulant medications have been sought 
by healthy individuals in order to improve cognitive function 
(14-16). Modafinil has been shown to improve 
neuropsychological performance, improve short term 
memory, and boost the individual’s ability to plan and process 
information when used at doses of 100 or 200 mg in healthy 
individuals (14,15,17). In a poll of 1,400 individuals 
conducted by the University of Cambridge, 1 in 5 respondents 
reported that they had taken cognitive enhancing medications 
for non-medical purposes to improve their focus and 
concentration (17). Of those who confirmed using cognitive 
enhancing medications, 44% reported using modafinil.  
To our knowledge, no study to date has investigated the 10-
year trend in modafinil exposures reported to poison control 
centers in the United States. Therefore, we performed a 
retrospective review of modafinil overexposure as reported to 
American poison information centers in order to determine 
whether an increased incidence of modafinil exposures was 
observed. Secondarily, we sought to determine which 
wwwwwwwwwwwwwwww 
  
populations were most likely to experience a resulting adverse 
clinical effect. 
 
 
A retrospective review of all cases of modafinil exposure 
reported to the American Association of Poison Control 
Centers (AAPCC) National Poison Data System (NPDS) was 
conducted. Cases are voluntarily reported to American poison 
information centers via a national telephone number and can 
involve adverse reactions, unintentional or intentional 
ingestions, or bites/envenomations. Data were reported to the 
AAPCC by poison information centers within the United 
States. One of the authors (EPK) was awarded a data grant by 
the AAPCC for those data reported to the AAPCC from 2001 
to 2010. Prior to analysis, these data were extracted from a 
Microsoft® Access database and converted to a Microsoft® 
Excel database. Modafinil exposures were identified using 
unique seven-digit product codes for modafinil and Provigil. 
Inclusion criteria were single substance exposure to modafinil 
and follow-up to a known outcome. Exclusion criteria were 
cases with history of coingestion of other medications and the 
inability to follow patients to a known outcome. 
 
 METHODS 
 
Table 1. Pertinent National Poison Data System (NPDS) coding field definitions 
Field Definition 
Acuity of exposure 
Acute Exposure that occurred over a period less than or equal to 8 hours. 
Acute-on-chronic A single ingestion that was preceded by an exposure occurring over a period exceeding 8 hours. 
Chronic Exposure to the same substance over a period exceeding 8 hours. 
Reason for exposure 
Unintentional – general Exposure that does not meet the description as detailed below.   
Unintentional – environmental Passive exposures that do not occur in the workplace involving contamination of air, soil, or water. 
Unintentional – occupational Exposure that occur as a direct result of the patient being in the workplace or on the job. 
Unintentional – therapeutic error Inadvertent deviations from proper therapeutic dosing instructions. 
Unintentional – misuse 
Exposure that is not planned and is unforeseen involving the wrongful use of a non-pharmaceutical 
substance.  
Unintentional – bite/sting All animal bites and stings, regardless of whether or not the patient is envenomated. 
Unintentional – food poisoning Suspected or confirmed food poisoning. 
Unintentional – unknown Exact reason of the unintentional ingestion is unknown. 
Intentional – suspected suicide Substance is ingested in a self-harm attempt. 
Intentional – misuse Improper use of a substance for reasons other than psychotropic effects. 
Intentional – abuse  Improper use of a substance in an attempt to gain a high, euphoric or psychotropic effect. 
Intentional – unknown Exact motive for intentional ingestion is unknown. 
Adverse reaction – drug 
Undesired symptoms secondary to an allergic, hypersensitivity, or idiopathic response to the active 
ingredients, inactive ingredients, or excipients of a substance. 
Medical outcome 
No effect No symptoms develop as a result of the exposure. 
Minor effect Some symptoms develop as a result of the exposure but they are minimally bothersome to the patient. 
Moderate effect 
The patient exhibits symptoms as a result of the exposure that are not life-threatening and no residual 
disability or disfigurement results. 
Major effect 
Patient develops life-threatening symptoms or significant residual disability/disfigurement as a result 
of the exposure. 
Death Patient died as a result of the exposure. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Characteristics of reported modafinil overexposures by medical outcome 
 Age (years) Gender Acuity Reason 
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No effect 532 286 65 42 73 55 276 256 451 74 3 10 8 57 453 1 1 
Effect 568 81 67 124 171 95 223 344 385 143 26 37 44 146 262 69 10 
 Minor 339 60 36 67 93 61 137 202 234 83 18 20 25 66 185 38 5 
 Moderate 222 21 31 55 74 33 82 139 146 58 8 17 18 76 75 31 5 
 Major 7 0 0 2 4 1 4 3 5 2 0 0 1 4 2 0 0 
Total 1100 367 132 166 244 150 499 600 836 217 29 47 52 203 715 79 13 
 
 
All personal identifiers were cleansed from the data prior to 
its receipt by investigators. Data collected included date of 
reported exposure, age, gender, reason for exposure, acuity of 
exposure and clinical outcome. Standard definitions for acuity 
of exposure, reason for exposure and medical outcomes were 
used by all US poison centers, the details of which are 
highlighted in Table 1 (18). Clinical manifestations of reported 
cases were not collected as the clinical effects of modafinil 
overdose have been previously described (2,3,12,13).  
Statistical analysis was performed using SPSS version 19 
(IBM Corp., Armonk, NY, USA). Odds ratios obtained from 
binomial logistic regression were used to estimate the risk of 
experiencing a clinical effect from modafinil ingestion 
according to age, acuity of exposure, and reason for exposure. 
Individual outcomes including “minor effect”, “moderate 
effect” and “major effect” were combined for the multivariate 
logistic regression. Unadjusted odds ratios were calculated to 
determine whether a variable (age, reason, or acuity) had an 
effect on outcome. Adjusted odds ratios were calculated to 
determine whether a variable (age, reason, or acuity) has an 
effect on clinical outcome when the other two variables were 
held constant. This study was determined to be exempt by the 
University of Pittsburgh Institutional Review Board.   
 
 
A total of 2,154 cases of modafinil ingestion were 
reported to the NPDS between 2001 and 2010. The trend in 
reported exposures is illustrated in Figure 1. As it is shown, 
the frequency of reported modafinil exposures has not 
continued to rise over time. A notable rise occurred prior to 
2008, with a peak of 162 cases reported in 2007. Thereafter, 
exposures declined toward levels observed during the first 
three years of the study period.  
After excluding cases that were confirmed non-exposures 
and those that lacked follow-up to a known outcome, 1,100 
cases were enrolled in the study. Table 2 shows the patient 
characteristics for reported overexposures according to medical 
outcome. Of all reported modafinil ingestions, 600 cases (54%) 
involved female patients. Three hundred sixty-seven patients 
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(35%) were less than or equal to 5 years of age and 244 (23%) 
were between 30 and 49 years of age. No clinical effect was 
observed in 532 cases (48%). Three hundred two exposures 
(27%) were intentional. Of the intentional exposures, 203 cases 
(67%) were suspected suicide attempts and 47 (16%) were 
reported abuse. Table 3 shows the reason for ingestion 
according to age. Abuse was reported most frequently in the 
18-29 and 30-49 year-old age groups with 17 exposures 
reported in each group.  
Results of the binomial logistic regression can be seen in 
Table 4. Patients 18-29 years of age were 4.6 times more 
likely to experience an adverse clinical effect as a result of 
modafinil ingestion as compared to patients 0-5 years of age 
(OR = 4.6; 95% CI 2.7-7.7; P < 0.001). Compared to patients 
5 years old or younger, all other age groups were more likely to 
experience a clinical effect. Results remained significant after 
controlling for reason and acuity. Compared to unintentional 
exposures, all other exposure types were more likely to 
experience an adverse clinical effect; after controlling for age 
and acuity, the results remained significant. Acute- 
wwwwwwwwwwwwwwwwwwwwwwww 
 
 RESULTS 
 
 
 
Figure 1. Frequency of reported modafinil exposures from January 
1st 2001 through December 31th 2010, by year (n = 2154) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
on-chronic exposures were more likely to experience a 
clinical effect (OR = 2.3; 95% CI 1.7-3.1; P < 0.001) than 
acute exposures. After controlling for age and reason, this 
likelihood was no longer significant. 
 
 
Optimization of cognitive performance is purportedly 
popular at colleges and universities in the United States. 
Students and professors have reported using cognitive 
enhancement drugs in order to improve their performance and 
productivity (19). Extending beyond the collegiate setting, the 
US military has investigated the use of pharmaceutical agents, 
such as modafinil, to improve neuropsychological function 
(17,19). Modafinil has been investigated as a potential aid in 
enhancing cognitive function in healthy adults (14,15). With 
wwwwwwwwwwwwwww 
the desire to outperform colleagues, one might expect a 
rising trend in the use and abuse of medications like 
modafinil. However, our study evaluated the trend in 
modafinil ingestion over a ten-year period and found only 
4% of all reported exposures to be due to abuse.   
A peak in modafinil ingestions was observed prior to 2008. 
Certain events related to the marketing of modafinil are 
important to note. The producer of modafinil, Cephalon Inc., 
was sued by multiple US states for promoting the off-label use 
of modafinil (20). As a result, in 2008, a multi-million dollar 
settlement was made. In our study, a notable decrease in 
reported ingestions occurred beginning in 2008. Penaloza et al. 
found that 89% of all patients prescribed modafinil are taking 
the medication for off-label uses, with depression and multiple 
sclerosis accounting for the largest portion of these off-label 
indications (20). Given that the majority of patients prescribed 
modafinil were taking the medication for an off-label 
indication, the drop in exposures reported may potentially be 
explained by the settlement in 2008. Furthermore, a fictitious 
press release was allegedly disseminated in 2008 that reported 
that the National Institute of Health was “cracking down on 
scientists’ brain doping” (21). This press release purportedly 
linked readers to a webpage for the World Anti-Brain Doping 
Authority, which was likewise fabricated (21). This spurious 
press release may have caused a decline in the use modafinil for 
this purpose. Lastly, the total number of human exposure calls 
reported to American poison information centers, however, also 
declined beginning in 2008 through 2010, which may also 
explain the decrease in exposure calls involving modafinil (22). 
Reported ingestions in college-aged individuals and those in 
the age range of 18-29 years, only accounted for 16% of all 
reported modafinil exposures over the study period. 
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 DISCUSSION 
Table 3. Reason for reported modafinil overexposures by age 
Reason 
Age (years) 
≤5 6-17 18-29 30-49 >50 
Intentional 
     
     Abuse 0 9 17 17 1 
     Misuse 0 3 19 18 7 
     Suspected suicide 0 35 68 72 20 
Unintentional 366 79 41 111 103 
Adverse Reaction 1 5 17 22 17 
Other 0 1 4 4 2 
Total 367 132 166 244 150 
 
Table 4. Risk of experiencing a clinical effect according to age, reason and acuity of exposure 
Risk Factor 
Unadjusted OR 
(95% CI) 
P value 
Adjusted OR 
(95% CI) 
P value 
Age (years) 
≤5 ---- ---- ---- ---- 
6-17 3.6 (2.3-5.4) < 0.001 2.3 (1.4-3.6) 0.001 
18-29 10.4 (6.8-16.0) < 0.001 4.6 (2.7-7.7) < 0.001 
30-49 8.3 (5.7-12.0) < 0.001 4.5 (2.9-6.9) < 0.001 
>50 6.1 (4.0-9.2) < 0.001 4.0 (2.5-6.4) < 0.001 
Reason 
Unintentional ---- ---- ---- ---- 
Intentional 5.2 (3.9-7.1) < 0.001 2.8 (1.9-4.0) < 0.001 
ADR 119 (16-864) < 0.001 51 (7-375) < 0.001 
Acuity 
Acute ---- ---- ---- ---- 
Acute-on-chronic 2.3 (1.7-3.1) < 0.001 1.0 (0.7-1.5) 0.88 
Chronic 10.2 (3.0-33.8) < 0.001 2.3 (0.6-8.4) 0.21 
OR: Odds ratio; CI: Confidence interval; ADR: Adverse drug reactions 
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 Furthermore, abuse was reported at the same frequency in the 
18-29 and 30-49 year-old age group. Despite reports 
propagated by the media, it does not appear that the 18-29 year-
old age group accounts for modafinil exposures at rates 
markedly higher than other age groups. Although the reason for 
ingestion could not be further classified beyond “misuse” and 
“abuse,” the small portion of ingestions by this age group may 
suggest that modafinil use for cognitive enhancement may not 
be as big of a problem as perceived by the media. Given the 
lower potential for abuse and the small number of FDA 
approved indications for modafinil, patients may be less apt to 
seek this medication individually for recreational purposes.   
 
 
Our study was limited by the fact that the frequency of 
modafinil ingestions was directly dependent on the exposure 
being reported voluntarily to one of the 57 poison control 
centers in the US and the inherent limitations of AAPCC NPDS 
data. Furthermore, we were unable to obtain national 
prescription rates over the ten-year period. Had we been able to 
normalize the number of reported exposures according to the 
number of prescriptions written per year, a more accurate 
representation of exposures accounting for a potential decrease 
in access to modafinil may have been possible.   
The presence of coingestants was excluded from our study 
in order to provide a more accurate portrayal of the clinical 
effects of supratherapeutic modafinil ingestions, which may 
have decreased the number of cases included in this study.   
 
 
A continual increase in modafinil exposure over the ten-year 
period was not observed. After 2007, the frequency of reported 
exposures decreased toward the frequency of ingestions 
reported during the first three years of the study period. The 
majority of reported exposures involved females, and children 
aged less than or equal to 5 years of age. Acute, unintentional 
exposures were most common and modafinil overexposures 
usually resulted in no clinical effect. Compared to patients less 
than or equal to 5 years of age, all other age groups were more 
likely to experience a clinical effect. Intentional exposures were 
more likely to experience a clinical effect.  
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